Thomas E. D'Ambra, founder of Albany Molecular Research (AMRI), will retire as president and chief executive officer of the firm at year's end, the company announced this morning.
William S. Marth, now non-executive chairman of the company's board, will succeed D'Ambra.
D'Ambra will remain with the firm as the non-executive chairman of the board of directors.
Marth joined AMRI as a member of the board of directors in June 2012. He was formerly president and chief executive officer of Teva Americas, a specialty pharmaceutical company.
AMRI, founded in 1991, is a research and manufacturing organization that focuses on drug discovery and development projects.